MAIA Biotechnology advances ateganosine with Fast Track and Phase 3 NSCLC trial
Rapid Pipeline Progress and Clinical Trials
MAIA Biotechnology files its annual report describing rapid progress for its lead cancer drug, ateganosine (THIO), and a growing telomere-targeting pipeline. The company is running the pivotal Phase 2 THIO-101 trial in third-line non-small cell lung cancer (NSCLC) and has initiated the Phase 3 THIO-104 trial comparing ateganosine plus a checkpoint inhibitor to chemotherapy in up to 300 patients.
Encouraging Survival Data
Ateganosine has shown encouraging interim results in NSCLC, including median overall survival around 17.8 months in heavily pretreated third-line patients, strong disease control and overall response rates, and generally manageable safety.
FDA Designations and Global Collaborations
MAIA has secured multiple FDA designations, including Orphan Drug, Fast Track and rare pediatric disease status, and expanded global collaborations with Regeneron, BeiGene/BeOne and Roche, while building a second-generation telomere-targeting prodrug platform and an extensive patent estate.
Strategic Expansion and Future Outlook
The company is scaling into Phase 3 THIO-104, expanding THIO-101 globally, and broadening into HCC, SCLC and CRC via a supply deal for tislelizumab with BeOne Medicines, plus a master supply agreement with Roche for atezolizumab. A sizeable IP portfolio and second-generation prodrug candidates (e.g., MAIA-2021-20) extend the telomere-targeting platform, though ultimate outcomes still depend on confirmatory Phase 3 efficacy, safety, and regulatory decisions.
